We have come to the conclusion that Lonza’s profitability trigger will be its speciality chemicals business (LSI) as the more pharma-like CDMO and health & nutrition business (LPBN) are expected to report a more stable margin development in 2019 and most likely in 2020. As a reminder, the company guides on the (adjusted) core EBITDA margin. But a more striking trigger would be management’s plans on LSI, which are expected around mid-2020.
23 Sep 2019
LSI's bright future?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LSI's bright future?
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
23 Sep 2019 -
Author:
Martin Schnee -
Pages:
3
We have come to the conclusion that Lonza’s profitability trigger will be its speciality chemicals business (LSI) as the more pharma-like CDMO and health & nutrition business (LPBN) are expected to report a more stable margin development in 2019 and most likely in 2020. As a reminder, the company guides on the (adjusted) core EBITDA margin. But a more striking trigger would be management’s plans on LSI, which are expected around mid-2020.